

Journal of Visualized Experiments

Behavioral assessment of visual function via optomotor response and cognitive function via Y-maze in diabetic rats --Manuscript Draft--

Article Type:	Invited Methods Article - JoVE Produced Video
Manuscript Number:	JoVE61806R1
Full Title:	Behavioral assessment of visual function via optomotor response and cognitive function via Y-maze in diabetic rats
Corresponding Author:	Rachael Allen Atlanta VA Medical Center Decatur, Georgia UNITED STATES
Corresponding Author's Institution:	Atlanta VA Medical Center
Corresponding Author E-Mail:	restewa@emory.edu
Order of Authors:	Kaavya Gudapati Anayesha Singh Danielle A Clarkson-Townsend Rachael Allen
Additional Information:	
Question	Response
Please indicate whether this article will be Standard Access or Open Access.	Standard Access (US\$2,400)
Please indicate the city, state/province, and country where this article will be filmed . Please do not use abbreviations.	Decatur, Georgia, USA
Please confirm that you have read and agree to the terms and conditions of the author license agreement that applies below:	I agree to the Author License Agreement
Please specify the section of the submitted manuscript.	Behavior
Please provide any comments to the journal here.	

TITLE:

Behavioral Assessment of Visual Function via Optomotor Response and Cognitive Function via Y-Maze in Diabetic Rats

AUTHORS AND AFFILIATIONS:

Kaavya Gudapati^{1,2*}, Anayesha Singh^{1,3*}, Danielle Clarkson-Townsend^{1,4}, Andrew J. Feola^{1,2}, Rachael S. Allen^{1,2}

¹Center for Visual and Neurocognitive Rehabilitation, Atlanta VA Medical Center, Decatur, GA, USA

²Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, USA

³Department of Neuroscience, Emory University, Atlanta, GA, USA

⁴Gangarosa Department of Environmental Health, Emory University, Atlanta, GA, USA

*These authors contributed equally

Email addresses of co-authors:

Kaavya Gudapati (kgudapati3@gatech.edu)

Anayesha Singh (anayesha.singh@emory.edu)

Danielle Clarkson-Townsend (Danielle.clarkson-townsend@emory.edu)

Andrew Feola (andrew.feola@bme.gatech.edu)

Rachael Allen (restewa@emory.edu)

Corresponding author:

Rachael Allen (restewa@emory.edu)

KEYWORDS:

diabetic retinopathy, retina, Y-maze, optomotor response, exploratory behavior, spatial frequency, contrast sensitivity, spatial memory, spontaneous alternation

SUMMARY:

Neural degeneration in both eyes and brain as a result of diabetes can be observed through behavioral tests carried out on rodents. The Y-maze, a measure of spatial cognition, and the optomotor response, a measure of visual function, both provide insight into potential diagnoses and treatments.

ABSTRACT:

The optomotor response and the Y-maze are behavioral tests useful for assessing visual and cognitive function, respectively. The optomotor response is a valuable tool to track changes in spatial frequency (SF) and contrast sensitivity (CS) thresholds over time in a number of retinal disease models, including diabetic retinopathy. Similarly, the Y-maze can be used to monitor spatial cognition (as measured by spontaneous alternation) and exploratory behavior (as measured by a number of entries) in a number of disease models that affect the central nervous system. Advantages of the optomotor response and the Y-maze include sensitivity, speed of

testing, the use of innate responses (training is not needed), and the ability to be performed on awake (non-anesthetized) animals. Here, protocols are described for both the optomotor response and the Y-maze and examples of their use shown in models of Type I and Type II diabetes. Methods include preparation of rodents and equipment, performance of the optomotor response and the Y-maze, and post-test data analysis.

INTRODUCTION:

Over 463 million people live with diabetes, making it one of the largest global disease epidemics¹. One of the serious complications that arises from diabetes is diabetic retinopathy (DR), a leading cause of blindness for working-age American adults². In the next 30 years, the percentage of the population at risk for DR is projected to double, so it is crucial to find new ways of diagnosing DR in its earlier stages to prevent and mitigate DR development³. DR has conventionally been thought to be a vascular disease⁴⁻⁶. However, now with evidence of neuronal dysfunction and apoptosis in the retina that precedes vascular pathology, DR is defined to have neuronal and vascular components⁴⁻⁹. One way to diagnose DR would be to examine neural abnormalities in the retina, a tissue that may be more vulnerable to oxidative stress and metabolic strain from diabetes than other neural tissue¹⁰.

Declines in cognitive and motor function also occur with diabetes and are often correlated with retinal changes. Older individuals with Type II diabetes portray worse baseline cognitive performance and show more exacerbated cognitive decline than control participants¹¹. Additionally, the retina has been established as an extension of the central nervous system and pathologies can manifest in the retina¹². Clinically, the relationship between retina and brain has been studied in the context of Alzheimer's and other diseases but is not commonly explored with diabetes¹²⁻¹⁶. Changes in the brain and retina during the progression of diabetes can be explored using animal models, including the STZ rat (a model of Type I diabetes in which the toxin, streptozotocin or STZ, is used to damage pancreatic beta cells) and the Goto-Kakizaki rat (a polygenic model of Type II diabetes in which animals develop hyperglycemia spontaneously at around 3 weeks of age). In this protocol, a description for the Y-maze and the optomotor response to assess cognitive and visual changes in diabetic rodents, respectively, is provided. The optomotor response (OMR) assesses spatial frequency (similar to visual acuity) and contrast sensitivity by monitoring characteristic reflexive head tracking movements to gauge visual thresholds for each eye¹⁷. Spatial frequency refers to the thickness or fineness of the bars, and contrast sensitivity refers to how much contrast there is between the bars and the background (**Figure 1E**). Meanwhile, the Y-maze tests short-term spatial memory and exploratory function, observed through spontaneous alternations and entries through the arms of the maze.

Both tests can be performed in awake, non-anesthetized animals and have the advantage of capitalizing on innate responses of the animals, meaning that they do not require training. Both are relatively sensitive, in that they can be used to detect deficits early in the progression of diabetes in rodents, and reliable, in that they produce results that correlate with other visual, retinal, or behavioral tests. Additionally, using the OMR and the Y-maze in conjunction with tests such as electroretinogram and optical coherence tomography scans can provide information on when retinal, structural, and cognitive changes develop relative to each other in disease models.

These investigations could be useful in identifying neural degenerations that occur due to diabetes. Ultimately, this could lead to new diagnostic methods that effectively identify DR in early stages of progression.

The OMR and the Y-maze systems used to develop this protocol are described in the **Table of Materials**. Previous research on the OMR, by Prusky et al.¹⁸, and the Y-maze, by Maurice et al.¹⁹, was used as the starting point to develop this protocol.

PROTOCOL:

All procedures were approved by the Atlanta Veterans Affairs Institutional Animal Care and Use Committee and conformed to the National Institutes of Health guide for the care and use of laboratory animals (NIH Publications, 8th edition, updated 2011).

1. The optomotor response (OMR)

1.1. Set up the OMR apparatus (details on apparatus and software in Table of Materials)

1.1.1. Choose the appropriate-sized platform for the rodent: mouse, rat, or large/impaired rat (**Figure 1A**).

1.1.2. Open the OMR software, which should open to a window with several tabs of options and a live video feed of the inside of the OMR/virtual drum (**Figure 1B**). Zoom in or out with the video camera as needed so that the platform and its surroundings are visible.

1.1.3. Note the icons along the left-hand side of the live image (**Figure 1C**). Click on the asterisk icon and the rotating stripes icon so that both the green asterisk and green rotating stripes disappear from the live feed.

1.1.4. Click on the **compass icon** so that a green circle and two perpendicular lines appear. Stretch the green circle so that it aligns perfectly with the black circle on the platform, which will ensure that the OMR is perfectly aligned.

1.1.5. Click on the **compass icon** because it is not necessary to see the circle during testing. Click on the **green asterisk icon** and the **green rotating stripes icon** to make these reappear. Note that the green stripes rotate in the same direction as the stripes in the drum, allowing the researcher to know the direction of the stripes.

1.1.6. Click on the **Testing** tab. Under **Testing**, click on the **Psychophysics** tab. Under **Threshold**, select **Frequency** to measure spatial frequency.

NOTE: The OMR software uses a staircase paradigm to automatically calculate spatial frequency (SF). Contrast will be maintained at 100%.

1.1.7. Under **Testing**, click on the **Presets** tab. Select the default settings for Mouse¹⁸ or Rat²⁰.

1.1.8. Under **Testing**, click on the **Blanking** tab. Check the **Blank on Tracking** box, which will pause the stripes/blank out the computer screens in the drum whenever the mouse is right-clicked.

1.1.9. Click on the **Results** tab, which is where the results of the test will be displayed.

1.2. Evaluate spatial frequency

1.2.1. Place the rodent on the circular platform in the center of the virtual reality chamber comprising four computer monitors showing vertical sine wave gratings circling the chamber at a velocity of $12^\circ/\text{s}$ (**Figure 1D**).

1.2.2. Note that the video camera positioned at the top of the chamber is projecting the rodent's behavior live onto the computer monitor.

1.2.3. Look for the presence or absence of reflexive actions by the rodent's head as the gratings move in a clockwise or counterclockwise direction. Make sure illustrated bars are visible in the program—these will show the direction of the grating movement.

1.2.3.1. Watch for the rodent's head to move in the same direction as the gratings. Wait until there is a smooth pursuit, not erratic bursts of head motion, to count it as tracking.

1.2.3.2. Click on **Yes** or **No** as appropriate. Note that SF will start with 0.042 cyc/deg and adjust with each yes and no to become easier or more difficult (**Figure 1E**). Click on **Reset** if the test needs to be reset due to accidental or incorrect clicking of yes and no.

1.2.4. As the rodent is tested, make sure to keep the asterisk positioned over the rodent's head.

NOTE: This has two effects: 1) It maintains the correct spatial frequency. If the asterisk is positioned between the shoulders, for example, the spatial frequency will be lower and the bars will be easier to see, resulting in a falsely high score. 2) For rodents with slight head movements, the asterisk makes it easier to gauge whether the head is actually moving.

1.2.5. Watch for the system to say "Done" when the rodent's spatial frequency is reached. Note that the **Yes** and **No** buttons will no longer be clickable.

1.2.6. Click on the **Results** tab, which will display the spatial frequency for the left eye, right eye, and combined eyes.

NOTE: Sometimes the software is set such that the results are flipped, i.e., the right eye is reported as the left eye and the left eye is reported as the right eye. This was discovered when assessing rodents that had only one eye lesioned in a glaucoma model.

1.3. Evaluate contrast sensitivity

NOTE: Contrast Sensitivity testing can be performed immediately after the spatial frequency measurement step or on its own on the same day or a different day if the rodent appears fatigued after spatial frequency testing (follow steps 1–2.2 if only testing contrast sensitivity).

1.3.1. Click on the **Testing** tab and then on the **Psychophysics** tab. Under **Threshold**, select **Contrast** (single) to measure contrast sensitivity.

1.3.2. Also using a staircase paradigm, start gratings with SF constant at the peak of the Contrast Sensitivity (CS) curve. To do this, click on the **Stimulus** tab and then on the **Gratings** tab. In the **Spatial Frequency** box, type **0.064** for rodents and **0.103** for mice.

1.3.3. Begin the contrast at 100% and look for the same reflexive head movements as seen during spatial frequency testing. Note that the contrast will decrease as the testing progresses until the rodent no longer has reflexive head movements in response to the stimulus (**Figure 1E**).

1.3.4. Watch for the system to say “Done” and the **Yes** and **No** buttons to no longer be clickable once the rodent no longer responds to the visual stimulus and the contrast sensitivity threshold has been reached. Click on the **Results** tab, where the contrast sensitivity for the left eye, right eye, and combined eyes will be listed.

1.4. Perform post-testing analysis

1.4.1. For diabetic retinopathy studies, where both eyes are expected to have similar deficits, use the combined score (average of right and left eyes) for analysis. For models that cause differential damage to eyes (i.e., blast injury or glaucoma), keep the left and right eye data separate.

1.4.2. For Spatial Frequency, use raw scores (the data from the **Results** tab) for analysis and average these scores together by group (i.e., diabetic, control, etc.).

1.4.3. For Contrast Sensitivity, use the raw value to calculate the reported contrast sensitivity by the Michelson contrast from a previous measurement of the screen’s luminance.

2. The Y-maze

2.1. Prepare rodents for testing

2.1.1. Adapt rodents to the room for 30 min prior to testing.

NOTE: The researcher can remain in the room with the lights on but should remain silent during this time.

2.1.2 Clean the Y-maze with sanitizing solution safe for animals and wipe away all sanitizing solution with paper towels. Ensure that the maze is dry.

2.2. Conduct the Y-maze

2.2.1. Label the initial arm of the Y-maze as B and the other 2 arms as A and C (**Figure 2A**). Place one rodent in the arm closest to the researcher (arm B) near the center of the Y-maze. Once the rodent has been placed, start the timer (details on maze and timer in **Table of Materials**).

2.2.1.2. Allow each rodent to explore the Y-maze for 8 min. Take recordings during this time and note any observations. Sit several feet away from the maze while keeping it in sight and avoid making any noise.

2.2.1.3. Record the starting location as A, and each time the rodent makes an entry into a new arm, record the new location of the rodent (**Figure 2B**). Define an entry as all four limbs of the rodent being in one of the arms.

2.2.1.4. Watch for rodents to hide and remain stationary in one arm of the maze. If the rodent remains in the same spot for more than 60 s and does not appear to show exploratory behavior, move the rodent toward the center of the Y-maze, and continue the trial.

2.2.2. After each rodent, remove any feces and clean the maze with sanitizing solution.

2.2.2.1. Ensure that all sanitizing solution is wiped away with paper towels and the maze is completely dry before placing the next rodent in the maze.

3. Calculate spontaneous alternation and exploratory behavior

2.3.1. Calculate exploratory behavior as the total number of entries made during 8 min.

2.3.2. Calculate spatial cognition as measured by spontaneous alternation:

the number of successful alternations/(the total number of entries - 2)

2.3.2.1. Define a successful alternation as the rodent moves into three different locations sequentially (Example: ABC, CAB, BCA, etc.). Note each successful alternation (**Figure 2B**).

2.3.2.2. If the movements were recorded as ACABCABABCABC, disregard the two initial starting locations when calculating spontaneous alternation (such that there are 11 movements in the denominator). Count the number of accurate movements (accurate movements = 8). Calculate the percent accuracy as: $8/(13 - 2) = 72.7\%$.

REPRESENTATIVE RESULTS:

The OMR is considered successful if spatial frequency and contrast sensitivity thresholds can be obtained from a rodent. Here, the use of the OMR to assess spatial frequency is illustrated in naïve control Brown-Norway and Long-Evans rats, both young (3–6 months) and aged (9–12

months). Brown-Norway rats typically show a higher baseline spatial frequency than Long-Evans rats. Additionally, an aging effect on spatial frequency was observed in the Long-Evans rats (**Figure 3A**). Data were analyzed using a one-way ANOVA followed by Holms-Sidak post-hoc comparisons as the young and aged results came from different cohorts.

The use of the OMR to assess contrast sensitivity is illustrated in the STZ model of Type I diabetes that received exercise intervention treatment. Long-Evans rats were assigned to one of the four groups: control, control + active, diabetic, and diabetic + active. Diabetic rats were given intravenous injections of the toxin STZ to damage the pancreatic beta cells and induce hyperglycemia. Active rats received 30 min of treadmill exercise, 5 days a week. Inactive rats had a locked treadmill so they would go back and forth between sitting in their cage and the inactive treadmill. Significant deficits in contrast sensitivity (**Figure 3B**) were observed in diabetic rats. Exercise treatment reduced these deficits (**Figure 3B**). These results demonstrate that the OMR is useful both for detecting and tracking retinal deficits over time and for assessing the effects of treatments and interventions on retinal disease²². Data were analyzed using a two-way repeated measures ANOVA followed by Holms-Sidak post-hoc comparisons. Note that results may be presented as data normalized to control (**Figure 3B**) or as raw values (**Figure 3A**; for spatial frequency: in cycles/degree or c/d; for contrast sensitivity: arbitrary units or a.u.). Typically, 6–10 animals, depending on severity of injury, are needed to find a significant difference with the OMR.

The Y-maze is considered successful if the rodent enters at least 5 arms of the maze within 8 minutes. Here, the ability of the Y-maze to assess cognitive function and exploratory behavior is illustrated in the Goto-Kakizaki rat, a polygenic, non-obese model of Type II diabetes that develops moderate hyperglycemia beginning at 2–3 weeks of age and does not require insulin supplementation. Significant deficits in spatial cognition, as measured by spontaneous alternation (**Figure 4A**), and exploratory behavior, as measured by number of entries (**Figure 4B**), were observed in Goto-Kakizaki rats compared with Wistar controls beginning at 7 weeks of age. Control rats seem to show a decrease in exploratory behavior over time. This trend is also observed in long term studies (8+ months of age). The decrease in movement could be due to lack of novelty with repeated maze exposure or a general decreased movement with age. Control rats appear to show an increase in spatial cognition over time. This trend is *not* observed in long-term studies in which the animals are run monthly instead of weekly (in fact, a decline with aging is often observed), and thus, this increase in spatial cognition may be due to a learning effect of running the maze once a week. Data were analyzed using a two-way repeated measures ANOVA followed by Holms-Sidak post-hoc comparisons. A minimum of 10 animals, depending on severity of injury, are typically needed to find a significant difference with the Y-maze.

This protocol generated visual function and cognitive function data in models of Type I and Type II diabetes. Scores for individual animals were averaged together and used to detect significant differences between treatment groups early in the progression of diabetes. Performing both retinal and cognitive assessments over time in models of systemic diseases such as diabetes allows for the monitoring of the temporal appearance of deficits over time. For example, in the Goto-Kakizaki model, retinal function deficits were shown to precede cognitive and exploratory

behavior deficits²³ (Figure 5).

FIGURE AND TABLE LEGENDS:

Figure 1: Setup of the OMR equipment. (A) Picture of mouse, rat, and large or impaired rat platforms. (B) Picture of computer screen during testing. (C) Panel of buttons during testing. (D) Schematic of rat on platform in chamber. (E) Example gradients showing increasing spatial frequency and contrast sensitivity.

Figure 2: Setup of the Y-maze equipment. (A) Picture of the Y-maze with arms labeled. (B) Picture of a lab notebook with example the Y-maze recording.

Figure 3: Using the OMR to track visual function. (A) Spatial frequency thresholds for young (n = 11) and aged (n = 15) Brown-Norway (BN) and young (n = 20) and aged (n = 13) Long-Evans (LE) rats. This figure presents Brown-Norway data from Feola et al., 2019²¹. (B) Using the OMR to track reduced retinal function over time and protective effects of exercise in an STZ rat model of Type I diabetes. Contrast sensitivity thresholds for inactive diabetic rats vs. active diabetic rats and control rats. Dark gray asterisks represent differences between both control groups and both diabetic groups. Orange asterisks represent differences between inactive diabetic rats and active diabetic rats. This figure presents data from a subset of rats from Allen et al., 2018²². Mean \pm SEM. ** p < 0.01, *** p < 0.001.

Figure 4: Using the Y-maze to track cognitive function and exploratory behavior over time in the Goto-Kakizaki model of Type II diabetes compared with Wistar controls. (A) Cognitive function (spontaneous alternation) for Goto-Kakizaki (diabetic) and Wistar (control) rats from 4 to 8 weeks of age. (B) Exploratory behavior (number of entries) from 4 to 8 weeks of age. Mean \pm SEM. ** p < 0.01, *** p < 0.001. Asterisks represent differences between Goto-Kakizaki and Wistar rats at each timepoint. Only one cohort of rats was run from 4 weeks to 8 weeks (GK: n = 7; Wistar: n = 10). All other cohorts were run from 5 weeks to 8 weeks (GK: n = 22; Wistar: n = 23) for a total n of 29 (GK) and 33 (Wistar) at weeks 5 through 8. This figure has been modified from Allen et al., 2019²³.

Figure 5: Timeline of functional changes in the Goto-Kakizaki model of Type II diabetes. After the appearance of hyperglycemia, the first changes observed in the Goto-Kakizaki rat were in retinal function, as measured by electroretinogram (ERG), appearing at 4 weeks of age. Cognitive and exploratory behavior changes appeared after 6 weeks of age. This figure has been modified from Allen et al., 2019²³.

DISCUSSION:

The OMR and the Y-maze allow for the non-invasive assessment of visual function and cognitive function deficits in rodents over time. In this protocol, the OMR and the Y-maze were demonstrated to track visual and cognitive deficits in rodent models of diabetes.

Critical steps in the protocol

The OMR

Some important points to consider when performing the OMR to assess visual function are the testing parameters used, experimental design and timing of testing, and experience of the researcher performing the measurements. One of the more critical steps in the protocol is to make sure that the parameters are correctly set. Additionally, as part of the setup, the OMR chamber should be cleaned with sanitizing solution or another approved disinfectant prior to and after each rodent. It is also important that the researcher performing the measures has been trained and is experienced in performing the measures. Best results are seen when the rodents are calm and acclimated to the room by leaving them in their cages for 30 min before starting the experiment. It is also important to determine baseline spatial frequency and contrast sensitivity whenever beginning work with a new strain and to note that not all strains will exhibit the same baseline levels. Brown-Norway rats have greater baseline spatial frequency than Long-Evans rats. Meanwhile, some strains of albino rats seem to have compromised spatial frequency²⁴, while other strains of albino rats do not exhibit tracking behavior at all. Many factors may contribute to the limited response of albino animals on the OMR: disturbed binocularity due to differential decussation of optic nerve fibers, lack of melanin in the back of the eye, and large proportion of dual opsin cones. Regardless, albino rats may not be appropriate subjects for the OMR testing since their performance could be too close to the limit of detection.

The Y-maze

A critical component of performing the Y-maze involves minimizing disturbances during the recording period. The initial placement of the rodent in the maze should only be done after allowing the rodent to acclimate to the room for 30 min. This allows the rodent to become adjusted to the new environment and prevents any confounding factors from impacting the rodent's normal behavior. Minimizing disturbances during each trial is very important. This includes avoiding loud noises and making sure the researcher is out of sight of the rodent. These distractions may cause stress to the rodent. It is also important to note that the walls of the room should remain as bare as possible with a neutral color. Any bright colors on the walls or posters may distract the rodent and can impact their exploratory behavior pattern.

Limitations of the method and modifications and troubleshooting of the method

The OMR

A potential limitation of the OMR measures is that it can be affected by experimenter bias, and different experimenters can have slightly different results since the OMR scoring is subjective. It can be easy to miss a head movement that is too subtle or classify exploratory behavior as a head movement. Because bias can affect the OMR outcomes, it is best if the experimenter is masked to treatment group and study design when possible. The development of an automatic OMR or comparing the results of two testers could also help to decrease experimenter bias.

One common issue that can occur during the OMR testing is when the rodent repeatedly jumps off the platform, making it difficult to obtain a visual threshold. If this happens, take note of it and gently place the rat back on the platform; it may also be necessary to measure the rat again the following day. Additionally, rats that have never been measured before might engage in exploratory behaviors when placed in the OMR. If this is an issue, having an additional baseline measure a week or so after the first measurement may help improve accuracy. Tests with excessive amounts of these behaviors should be discarded.

Other factors such as age or olfactory cues could also contribute to unwanted activity. Therefore, it is important to design experiments in accordance with the timeline of visual system development in rats and to thoroughly clean the platform and chamber before and after testing each rodent. The time of day the OMR measurements are performed should also be considered, as previous studies have shown that there are circadian rhythms in spatial frequency²⁵. Running the rats before noon appears to be best for their focus (Rachael Allen's lab—personal observations). If rats become too distracted, it can help to gently tap on the outside of the OMR.

The speed with which the testing is performed can also affect results. Measures may become less accurate after 30 min or so if the rodents lose interest in the stimulus. Therefore, more accurate results may be obtained when measurements are taken in approximately ≤ 20 min. Duration of a single trial (for either SF or CS) is 5–10 min for an expert and 30 min for a beginner. If a rodent is showing little movement, spending most of its time grooming, or otherwise not looking in the direction of the bars, it may be fatigued. The rodent may be run again on a different day. Additionally, SF and CS testing can be performed on different days, particularly for newer testers who may be slower. The frequency with which the test is performed can also affect results—performing it weekly or every other week helps the animals stay acclimated to the test, but performing it every day or every other day can cause hyperacuity²⁶. We do not run more than one trial per day, though we often run both SF and CS on the same day or even in the same sitting. Cumulative daily time for running a cohort of rats ($n = 10$) is 2 h for an expert.

The OMR measures each eye independently, resulting in separate visual scores for each eye. In the Morrison and microbead models of glaucoma and in an optic nerve crush model, our lab has not observed any impact of the damaged eye on the undamaged eye²⁷. In a blast model, with the blast directed at one eye, the contralateral eye did show damage, but this could also be due to a partial blast effect²⁸. In control rats, there should be no difference in results between clockwise or counterclockwise directions, but some rodents could have a bias; thus, it would be best to alternate the directions²⁹, if the OMR system does not alternate automatically.

Depending on the disease model, treatment group differences in visual function can vary based on the parameters used. For example, when testing contrast sensitivity, if the spatial frequency is set to a level that is above the normal spatial frequency threshold and difficult to resolve, the differences in contrast sensitivity between groups will be small. However, if the spatial frequency is set to a level that is normally easy for rats to see, the differences in contrast sensitivity between groups will be larger³⁰. Therefore, it is important to consider study design and normal spatial frequency thresholds of rodents when setting parameters for performing the OMR.

The Y-maze

If an animal is scared, it may freeze in one corner of the maze. Additionally, if a loud noise happens outside the room, an animal may become scared and not move in the maze. To account for these issues, researchers can acclimate rats to the room first, move a frozen animal to a choice point, run an animal again on a different day, or run the animals in red light, which is thought to make them less nervous as they are normally active in darkness (David Weinschenker's Lab—personal communication). It is also recommended to run the Y-maze at the same time each day to account for changes in activity levels throughout the day due to circadian rhythms. We typically run the rats before noon (Rachael Allen's Lab—personal observations). Duration of a single trial is 8 min (10 min, with clean up). We never run more than one trial per day. If an additional trial is needed, the trial is performed on another day. Cumulative daily time for running a cohort of rats ($n = 10$) is 2–3 h. Age-related decreases in spatial alternation were observed in rats at 9–12 months of age and in exploratory behavior at 12 months of age²⁸.

While both exploratory behavior and spatial cognition decrease in diabetic rodents, the two do not appear to be tightly correlated, and thus, we do not independently evaluate locomotor activity prior to the Y-maze testing.

The significance of the method with respect to existing/alternative methods

The OMR

Other methods of visual function testing, such as optokinetic tracking, rely on fixing the animal's head in place and tracking eye movements. Unrestrained optomotor response (OMR) testing allows for longitudinal, non-invasive, and reliable measurement of visual function in rodents. In this protocol, it was described how the OMR can be used to quantify both spatial frequency and contrast sensitivity thresholds for each eye. This method can be very useful for detecting early stage neuronal dysfunction in diseases such as diabetes. Other tests such as the visual water task can also be used to measure spatial frequency³¹, but as this involves training rodents to swim toward a gradient in a modified Y-maze, the task is time consuming and involves a lot of training. Further, the OMR measures values for each eye independently, which is useful in models where injury is directed at one eye and the other eye serves as a contralateral control (for example, many glaucoma models). Additionally, OMR is a sensitive assessment, able to detect changes as early as 3–4 weeks post-diabetes, which is sooner than other visual assessments. Electrophysiological assays are an alternative to behavioral visual tests. Electroretinography (ERG) is more available than the OMR and can determine deficits in precise cell types using different components of the ERG wave³² (a- waves represent photoreceptor cell function, b- waves represent bipolar cell function). Meanwhile, the OMR can be used to determine a deficit visual function, without revealing the precise point of breakdown along the pathway. However, the OMR is a more sensitive measure of DR than ERG, with the OMR deficits typically observed between 2–4 weeks post hyperglycemia and ERG deficits typically observed 4–8 weeks post hyperglycemia in rodents. Severe diabetic cataracts can affect the OMR. However, diabetic

cataracts in rodents appear and/or worsen under anesthesia, and thus, tests such as ERG and optical coherence tomography that require anesthesia are affected much more often than the OMR, which is performed in awake animals.

The Y-maze

The Y-maze relies on spatial cognition like the Morris water maze but does not use a strong negative stimulus (i.e., water) to motivate the animal to perform the task. Thus, the Y-maze is less stressful for the animals and is also easier to perform. However, it is possible that the Y-maze may not be as sensitive as the Morris water maze or the Barnes maze. Unlike the Morris water maze, the Y-maze is an automatic behavior and does not require training. Thus, the time burden involved in performing the Y-maze is much lower.

Conclusions and future applications or directions of the method

The OMR

The OMR is useful for taking measurements of visual function in rodents by tracking head movements. It is an effective method, but there are updates and additions that are continuously made to improve the protocol. Some novel methods utilize the rodent pausing its head as a negative OMR indicator combined with head tracking as a positive indicator³³. This enables quicker and more accurate measures of visual function³⁴. Another way this process has been modified is to develop a system that will automatically track the head without artificial markers to reduce inconsistencies that could result from human testers³⁵. As of 2016, an automated or quantitative OMR system called qOMR has been well developed and is commercially available. In the above protocol, the OMR was able to detect deficits in spatial frequency and contrast sensitivity in diabetic rats, as well as protection against deficits with a treatment (exercise).

The Y-maze

The Y-maze reveals information about exploratory behavior and spatial cognition and was used here to detect behavioral deficits in diabetic rodents at 7 weeks. Other tests to observe cognitive function exist (i.e., Morris water maze, Barnes maze, novel object recognition), and it is possible that these tests may be able to reveal cognitive decline earlier or provide information about different aspects of cognition. Future directions for the Y-maze include placing a novel object or food stimulus in one of the arms and observing the exploratory pattern of the rodent³⁶. A variation of this involves blocking one of the arms of the Y-maze, allowing the rodent to explore the two remaining arms, and then reopening access to the third arm and evaluating how long the rodent spends in the third novel arm. Another valuable improvement that could be made regarding the Y-maze is developing automatic tracking of the rodents in order to record their movements. This would eliminate the need for manual recording of the rodents' movements and would make calculations of the spontaneous alternations more accurate and efficient.

ACKNOWLEDGMENTS:

This work was supported by the Department of Veterans Affairs Rehab R&D Service Career Development Awards (CDA-1, RX002111; CDA-2; RX002928) to RSA and (CDA-2, RX002342) to AJF and the National Institutes of Health (NIH-NICHD F31 HD097918 to DACT and NIH-NIEHS T32 ES012870 to DACT) and NEI Core Grant P30EY006360.

DISCLOSURES:

The authors have nothing to disclose.

REFERENCES:

1. IDF. International Diabetes Federation Diabetes Atlas, 9th edn. <https://diabetesatlas.org/upload/resources/material/20200302_133351_IDFATLAS9e-final-web.pdf> (2019).
2. Wang, W., Lo, A. C. Y. Diabetic retinopathy: pathophysiology and treatments. *International Journal of Molecular Sciences*. **19** (6) (2018).
3. Akpek, E. K., Smith, R. A. Overview of age-related ocular conditions. *The American Journal of Managed Care*. **19** (5 Suppl), S67–75 (2013).
4. Urano, F. Wolfram syndrome: diagnosis, management, and treatment. *Current Diabetes Reports*. **16** (1), 6 (2016).
5. Adeva-Andany, M. M., Funcasta-Calderón, R., Fernández-Fernández, C., Ameneiros-Rodríguez, E., Domínguez-Montero, A. Subclinical vascular disease in patients with diabetes is associated with insulin resistance. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*. **13** (3), 2198–2206 (2019).
6. Chin, J. A., Sumpio, B. E. Diabetes mellitus and peripheral vascular disease: diagnosis and management. *Clinics in Podiatric Medicine and Surgery*. **31** (1), 11–26 (2014).
7. Barber, A. J., Gardner, T. W., Abcouwer, S. F. The significance of vascular and neural apoptosis to the pathology of diabetic retinopathy. *Investigative Ophthalmology & Visual Science*. **52** (2), 1156–1163 (2011).
8. Pardue, M. T., Allen, R. S. Neuroprotective strategies for retinal disease. *Progress in Retinal and Eye Research*. **65**, 50–76 (2018).
9. Aung, M. H., Kim, M. K., Olson, D. E., Thule, P. M., Pardue, M. T. Early visual deficits in streptozotocin-induced diabetic long evans rats. *Investigative Ophthalmology & Visual Science*. **54** (2), 1370–1377 (2013).
10. Antonetti, D. A. et al. Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. *Diabetes*. **55** (9), 2401–2411 (2006).
11. Logroscino, G., Kang, J. H., Grodstein, F. Prospective study of type 2 diabetes and cognitive decline in women aged 70–81 years. *BMJ*. **328** (7439), 548 (2004).
12. London, A., Benhar, I., Schwartz, M. The retina as a window to the brain-from eye research to CNS disorders. *Nature Reviews Neurology*. **9** (1), 44–53 (2013).
13. Archibald, N. K., Clarke, M. P., Mosimann, U. P., Burn, D. J. The retina in Parkinson's disease. *Brain*. **132** (5), 1128–1145 (2009).
14. Sakai, R. E., Feller, D. J., Galetta, K. M., Galetta, S. L., Balcer, L. J. Vision in multiple sclerosis: the story, structure-function correlations, and models for neuroprotection. *Journal of Neuroophthalmology*. **31** (4), 362–373 (2011).
15. Wong, T. Y. et al. Retinal microvascular abnormalities and incident stroke: the

573 Atherosclerosis Risk in Communities Study. *The Lancet*. **358** (9288), 1134–1140 (2001).

574 16. Marquie, M. et al. Association between retinal thickness and β -amyloid brain
575 accumulation in individuals with subjective cognitive decline: Fundació ACE Healthy Brain
576 Initiative. *Alzheimer's Research & Therapy*. **12** (1), 37 (2020).

577 17. Thomas, B. B., Seiler, M. J., Sadda, S. R., Coffey, P. J., Aramant, R. B. Optokinetic test to
578 evaluate visual acuity of each eye independently. *Journal of Neuroscience Methods*. **138** (1–2),
579 7–13 (2004).

580 18. Prusky, G. T., Alam, N. M., Beekman, S., Douglas, R. M. Rapid quantification of adult and
581 developing mouse spatial vision using a virtual optomotor system. *Investigative Ophthalmology
582 & Vision Science*. **45** (12), 4611–4616 (2004).

583 19. Maurice, T. et al. Behavioral evidence for a modulating role of σ ligands in memory
584 processes. I. Attenuation of dizocilpine (MK-801)-induced amnesia. *Brain Research*. **647** (1), 44–
585 56 (1994).

586 20. Douglas, R. M. et al. Independent visual threshold measurements in the two eyes of freely
587 moving rats and mice using a virtual-reality optokinetic system. *Visual Neuroscience*. **22** (5), 677–
588 684 (2005).

589 21. Feola, A. J. et al. Menopause exacerbates visual dysfunction in experimental glaucoma.
590 *Experimental Eye Research*. **186**, 107706 (2019).

591 22. Allen, R. S. et al. TrkB signalling pathway mediates the protective effects of exercise in the
592 diabetic rat retina. *European Journal of Neuroscience*. **47** (10), 1254–1265 (2018).

593 23. Allen, R. S. et al. Retinal deficits precede cognitive and motor deficits in a rat model of
594 type II diabetes. *Investigative Ophthalmology & Vision Science*. **60** (1), 123–133 (2019).

595 24. Prusky, G. T., Harker, K. T., Douglas, R. M., Whishaw, I. Q. Variation in visual acuity within
596 pigmented, and between pigmented and albino rat strains. *Behavioural Brain Research*. **136** (2),
597 339–348 (2002).

598 25. Hwang, C. K. et al. Circadian rhythm of contrast sensitivity is regulated by a dopamine-
599 neuronal PAS-domain protein 2-adenylyl cyclase 1 signaling pathway in retinal ganglion cells.
600 *Journal of Neuroscience*. **33** (38), 14989–14997 (2013).

601 26. Mui, A. M. et al. Daily visual stimulation in the critical period enhances multiple aspects
602 of vision through BDNF-mediated pathways in the mouse retina. *PLoS One*. **13** (2), e0192435
603 (2018).

604 27. Feola, A. J. et al. Menopause exacerbates visual dysfunction in experimental glaucoma.
605 *Experimental Eye Research*. **186**, 107706 (2019).

606 28. Allen, R. S. et al. Long-term functional and structural consequences of primary blast
607 overpressure to the eye. *Journal of Neurotrauma*. **35** (17), 2104–2116 (2018).





608 29. Maaswinkel, H., Li, L. Spatio-temporal frequency characteristics of the optomotor
609 response in zebrafish. *Vision Research*. **43** (1), 21–30 (2003).


610 30. Benkner, B., Mutter, M., Ecke, G., Münch, T. A. Characterizing visual performance in mice:
611 an objective and automated system based on the optokinetic reflex. *Behavioral Neuroscience*.
612 **127** (5), 788–796 (2013).

613 31. Lehmann, K., Schmidt, K.-F., Löwel, S. Vision and visual plasticity in ageing mice.
614 *Restorative Neurology and Neuroscience*. **30**, 161–178 (2012).

615 32. Leinonen, H., Tanila, H. Vision in laboratory rodents-tools to measure it and implications
616 for behavioral research. *Behavioral Brain Research*. **352**, 172–182 (2018).

33. Spielmann, M., Schröger, E., Kotz, S. A., Pechmann, T., Bendixen, A. Using a staircase procedure for the objective measurement of auditory stream integration and segregation thresholds. *Frontiers in Psychology*. **4**, 534 (2013).
34. Shi, C. et al. Optimization of optomotor response-based visual function assessment in mice. *Scientific Reports*. **8** (1), 9708 (2018).
35. You, M., Yamane, T., Tomita, H., Sugano, E., Akashi, T. A novel rat head gaze determination system based on optomotor responses. *PLoS One*. **12** (4), e0176633 (2017).
36. Whyte, A. J. et al. Reward-related expectations trigger dendritic spine plasticity in the mouse ventrolateral orbitofrontal cortex. *The Journal of Neuroscience*. **39** (23), 4595–4605 (2019).





B

$$\frac{ID}{37} \quad \begin{array}{cccc} 1 & 1 & 1 & 1 \end{array} \quad \begin{array}{cccc} 1 & 1 & 1 & 1 \end{array} \quad ACABBCABABBCABC = \frac{8}{13-2}$$






Figure 4

A



B





Figure 5



Name of Material/Equipment	Company		Catalog Number	Comments/Description
OptoMotry HD	CerebralMechanics Inc.			OMR apparatus & software
Timer	Thomas Scientific		810029AR	
Y-Maze apparatus	San Diego Instruments		7001-043	Available specifically for rats



DEPARTMENT OF VETERANS AFFAIRS
Rehabilitation R&D Service
Center of Excellence for Visual and Neurocognitive Rehabilitation
Atlanta VA Medical Center (151R)
Decatur GA 30033-4004



September 3, 2020

Dear Dr. Upponi,

We are very pleased to re-submit our paper, entitled “Behavioral assessment of visual function via optomotor response and cognitive function via Y-maze in diabetic rats,” for publication in the *Journal of Visual Experiments*.

We thank the editors and reviewers for their insightful comments that have strengthened the manuscript. We are pleased that the reviewers thought the OMR and Y-maze descriptions “could be useful for researchers working in different fields”. We have made the requested revisions to the manuscript based on the editors’ and reviewers’ suggestions and have addressed the comments in a point-by-point fashion below, with changes throughout the manuscript in tracked changes.

We hope that the manuscript is now acceptable for publication.

Sincerely,

A handwritten signature in black ink that reads "Rachael Allen".

Rachael Allen, PhD
Career Development Awardee (CDA-2)
Atlanta VA Medical Center
Phone: (404)321-6111 x207570; Fax: (404)728-2847
restewa@emory.edu

Editorial Comments:

Changes to be made by the Author(s):

1. Please take this opportunity to thoroughly proofread the manuscript to ensure that there are no spelling or grammar issues.

Response: Thank you. We have carefully proofread the manuscript for spelling and grammar errors.

2. Please revise the table of the essential supplies, reagents, and equipment. The table should include the name, company, and catalog number of all relevant materials in separate columns in an xls/xlsx file. Please sort the Materials Table alphabetically by the name of the material.

Response: We have sorted the table alphabetically and included all equipment. Our OMR comes as one whole system, and the company does not use catalog numbers.

3. Please revise the text to avoid the use of any personal pronouns (e.g., "we", "you", "our" etc.).

Response: Thank you. We have adjusted all text to remove personal pronouns.

4. Please use the generic name for Quatricide instead of the brand name.

Response: We have changed Quatricide to "sanitizing solution" throughout.

5. Please do not abbreviate journal titles in the references.

Response: Thank you. We have spelled out all journal names.

Reviewers' comments:

Reviewer #1:

Manuscript Summary:

Good job. I will be interested in seeing the video.

Major Concerns:

- I would suggest removing no-brainers from the method description such as plugging the power strips etc.

Response: Thank you. We have removed this from the methods description.

- Discussion in row 337-342. Albino subjects are known of their bad vision, due to many factors including disturbed binocularity, lack of melanin in the back of the eye and large proportion of dual opsin cones. Please emphasize this point that albinos may not be good subjects for OMR testing because their performance may be too close to limit of detection.

Response: We agree that this is an important point and have modified the discussion as such:

"Meanwhile, some strains of albino rats seem to have compromised spatial frequency²², while other strains of albino rats do not exhibit tracking behavior at all. Many factors may contribute to the limited response of albino animals on OMR: disturbed binocularity due to differential decussation of optic nerve fibers, lack of melanin in the back of the eye, and large proportion of

dual opsin cones. Regardless, albino rats may not be appropriate subjects for OMR testing since their performance could be too close to the limit of detection."

- I would appreciate if authors could give guidelines if contrast sensitivity or spatial frequency threshold testing is better in respect to diabetes and maybe also retinal degenerations models? How about rotation speed? Temporal frequency?

Response: This is a great question, and something we wonder about as well. I am hesitant to say that particular aspects of OMR are more sensitive for a particular disease. I personally see SF change earlier in diabetic retinopathy models, but others in the lab have seen CS change earlier – and that is with the same model in the same lab. I just don't think we have definitive data on this.

- In OMRs alternative methods the authors do not mention electrophysiology at all, even if it may be the most precise way of detection visual dysfunction. ERG (however not with pattern stimulation) is also much more available than OMR. Please see and refer to e.g. Leinonen & Tanila 2018, Behav Brain Res.

Response: Thank you for the suggestion. We have modified the discussion and added this reference.

"Electrophysiological assays are an alternative to behavioral visual tests. Electroretinography (ERG) is more available than OMR and can determine deficits in precise cell types using different components of the ERG wave (a- waves represent photoreceptor cell function, b- waves represent bipolar cell function). Meanwhile, OMR can be used to determine a deficit visual function, without revealing the precise point of breakdown along the pathway. However, OMR is a more sensitive measure of DR than ERG, with OMR deficits typically observed between 2-4 weeks post hyperglycemia and ERG deficits typically observed 4-8 weeks post hyperglycemia in rodents."

- I would like if authors could very clearly state their opinions/recommendations of the:

1. Time of the day when OMR and Y-maze would be best performed
2. Duration of a single trial
3. How many trials per day is ok, and at what intervals?
4. Cumulative daily time.

Response: Good questions! We have added the following to the discussion:

OMR: *"Running the rats before noon appears to be best for their focus (Rachael Allen's lab – personal observations). If rats become too distracted, it can help to gently tap on the outside of the OMR.*

The speed with which the testing is performed can also affect results. Measures may become less accurate after 30 minutes or so if the rodents lose interest in the stimulus. Therefore, more accurate results may be obtained when measurements are taken in approximately ≤ 20 minutes. Duration of a single trial (for either SF or CS) is 5-10 minutes for an expert and 30 minutes for a beginner. If a rodent is showing little movement, spending most of its time grooming, or otherwise not looking in the direction of the bars, it may be fatigued. The rodent may be run again on a different day. Additionally, SF and CS testing can be performed on different days, particularly for newer testers who may be slower. The frequency with which the test is performed can also affect results – performing it weekly or every other week helps the animals stay acclimated to the test, but performing it every day or every other day can cause hyperacuity²⁴. We do not run more than one trial per day, though we often run both SF and CS in the same day or even the same sitting. Cumulative daily time for running a cohort of rats (n=10) is 2 hours for an expert."

Y-maze: *"It is also recommended to run the Y-Maze at the same time each day to account for changes in activity levels throughout the day due to circadian rhythms. We typically run the rats before noon (Rachael Allen's Lab – personal observations). Duration of a single trial is 8 minutes (10 minutes, with clean up). We never run more than one trial per day. If an additional trial is needed, the trial is performed on another day. Cumulative daily time for running a cohort of rats (n=10) is 2-3 hours."*

Minor Concerns:

- Row 70: retina may be more vulnerable than what? Other tissues of the body?

Response: We have edited this to say, *"than other neural tissue¹²."*

- Row 91-92: This is just a stylistic matter, but are parentheses really needed here? I think text would flow smoother without.

Response: We have removed the parentheses.

- Row 94-95: I do not understand what authors are trying to say here. What about OCT and ERG? As if something is missing here.

Response: Thank you for catching this. We have adjusted the text so that it reads as such:

"Both are relatively sensitive, in that they can be used to detect deficits early in the progression of diabetes in rodents, and reliable, in that they produce results that correlate with other visual, retinal, or behavioral tests. Additionally, using OMR and Y-maze in conjunction with tests such as electroretinogram and optical coherence tomography scans can provide information on when retinal, structural, and cognitive changes develop relative to each other in disease models."

- Row 358: OMR scoring without automation IS subjective, not only CAN BE.

Response: Thank you. We have made this change.

- Row 361: A well functioning automated OMR has been developed and is commercially available (qOMR by Phenosys) and should be mentioned here.

Response: Thank you for the suggestion. We have added the following sentence but cannot state the company by name due to the journal's policy (we also do not state the companies who make our equipment by name).

"As of 2016, an automated or quantitative OMR system called qOMR has been well developed and is commercially available."

- Rows 399 and 401 - Weinshenker and Allen labs. Please give also first names. There is too many Allen last named PIs to make a distinction.

Response: Thank you. We have made this change.

- Figure 4. I am curious. Why is there such strong interaction? Why is exploratory behavior so high in GK rats initially?

Response: We are honestly wondering the same thing. The reviewers for that paper asked us to run an additional cohort that began at 4 weeks instead of 5 weeks, so the small cohort of rats run at 4 weeks (GK: n=7, Wistar: n=10) is the only group we have ever run at that timepoint. I'm reluctant to speculate on why it happens until I can be sure we see it again.

- Figure 5. ERG retinal = "electroretinography retinal". I suggest to put it: ERG/retinal function

Response: Thank you. We have adjusted this figure.

Reviewer #2:

Manuscript Summary:

The aim of the present report was to describe protocols for OMR and Y-maze tests in rats. In addition, the authors show the performance differences for diabetic and control rats in these tests. I think that the report could be useful for researchers working in different fields. However, there are some points that should be addressed before publication,

Major Concerns:

Introduction:

.... a tissue that may be more vulnerable to oxidative stress and metabolic strain from diabetes. More vulnerable than what? Please, rephrase

Response: Thank you. We have edited this to say, "*than other neural tissue*¹²."

Regarding this paragraph: Clinically, the relationship between retina and brain has been studied in the context of Alzheimer's Disease and other diseases but is not commonly explored with diabetes¹⁵; reference 15 refers exclusively to Alzheimer's Disease, to address other diseases (as mentioned in the text), other references should be added.

Response: We have included additional references for this statement.

Results

Regarding data shown in Figure 3 and 4, no information about the statistical analysis is provided. In addition, is highly confusing the number of animals (10-23?, 7-29?) used in Figure 4. It is not clear the meaning of the P value, particularly which groups are being compared. These are important issues. The authors should mention how many animals/group should be used to find significantly statistic differences among groups, and they should suggest the proper way to analyze the data from a statistical standpoint.

Response: Thank you for these important points. The issue with the number of animals is due to the reviewers for that paper asking us to run an additional cohort that began at 4 weeks instead of 5 weeks. We have added the following to the figure legend for Figure 4 as an explanation:

"Only one cohort of rats was run from 4 weeks to 8 weeks (GK: n=7; Wistar: n=10). All other cohorts were run from 5 weeks to 8 weeks (GK: n=22; Wistar: n=23) for a total n of 29 (GK) and 33 (Wistar) at weeks 5 through 8."

We have added the following information on statistical analysis to the results section:

OMR: *"Data were analyzed using a one-way ANOVA followed by Holms-Sidak post-hoc comparisons as the young and aged results came from different cohorts."*

“Data were analyzed using a two-way repeated measures ANOVA followed by Holms-Sidak post-hoc comparisons. 6-10 animals, depending on severity of injury, are typically needed to find a significant difference with OMR.”

Y-maze: “Data were analyzed using a two-way repeated measures ANOVA followed by Holms-Sidak post-hoc comparisons. A minimum of 10 animals, depending on severity of injury, are typically needed to find a significant difference with Y-maze.”

We have also added information to the figure legends about which groups are being compared with regard to p values.

For OMR, have the authors noticed differences between gratings moving in a clockwise and counterclockwise direction? Please, comment

Response: Thank you. We have added the following sentence to the discussion:

“In control rats, there should be no difference in results between clockwise or counterclockwise directions, but some rodents could have a bias so it would be best to alternate the directions if the OMR system does not alternate automatically.”

For models causing differential eye damage (e.g., glaucoma), have the authors noted any influence of the damaged eye on the undamaged eye?

Response: Thank you. We have added the following sentence to the discussion:

“OMR measures each eye independently, resulting in separate visual scores for each eye. In the Morrison and microbead models of glaucoma and in an optic nerve crush model, our lab has not observed any impact of the damaged eye on the undamaged eye. In a blast model, with the blast directed at one eye, the contralateral eye did show damage, but this could also be due to a partial blast effect.”

Please, make any comment on the inter-individual variability in normal and diabetic animals. Based on the data shown in Figure 3, it seems that this parameter (i.e., SEM) could be significantly different among groups. I believe that some "biological information" is hidden behind this issue.

The protective effect of exercise in diabetic rats regarding SF seems unclear (Figure 3A). In contrast, the exercise seems to be effective regarding the contrast sensitivity. Thus, the lack of correlation between the SF and the CS should be discussed. In addition, the authors should explain to potential readers the biological meaning of SF and CS.

Response: This is an important point about the SF results with exercise. When additional cohorts were run with active animals and active animals + a TrkB inhibitor, the SF and CS results did correlate, as published in Allen et al., 2018. We have decided to remove/replace Figure 3A – partly for this reason and partly because we wanted to include a new SF figure that shows strain and age differences with raw SF numbers for reference.

For the point about the biological meaning of SF and CS, we have added the following sentence to the introduction:

“Spatial frequency refers to the thickness or fineness of the bars, and contrast sensitivity refers to how much contrast there is between the bars and the background (Figure 1E).”

In Figure 4, it seems that control rats changed their performance in the Y-maze along the study (i.e, the spontaneous alternation seems higher at 8 than at 4 weeks), whereas the exploratory behavior seems to go in the opposite direction. As for diabetic GK rats in the same test, differences in spontaneous alternation and exploratory behavior along the study are dissimilar. Is there any rational explaining why exploratory behavior is much more sensitive to diabetic progression than spontaneous alternation? Please, check the intra-group statistic variability for normal and diabetic rats along the study.

Response:

Cognitive and exploratory behavior for control rats (added to results section): *“Control rats seem to show a decrease in exploratory behavior over time. This trend is also observed in long term studies (8+ months of age). The decrease in movement could be due to lack of novelty with repeated maze exposure or a general decreased movement with age. Control rats appear to show an increase in spatial cognition over time. This trend is not observed in long term studies in which the animals are run monthly instead of weekly (in fact, a decline with aging is often observed), and thus, this increase in spatial cognition may be due to a learning effect of running the maze once a week.”*

Exploratory behavior for diabetic rats: We are honestly wondering the same thing about why the 4 week exploratory behavior is so high for the GK rats. The reviewers for that paper asked us to run an additional cohort that began at 4 weeks instead of 5 weeks, so the small cohort of rats run at 4 weeks (GK: n=7, Wistar: n=10) is the only group we have ever run at that timepoint. I'm reluctant to speculate on why it happens until I can be sure we see it again. If you ignore the 4 week timepoint, the exploratory and cognitive behavior trends are more similar.

How much can diabetes-induced locomotor impairment affect spatial cognition in the Y-maze test? Do the authors consider it necessary to independently evaluate locomotor activity in diabetic rats, before the Y-maze test?

Response: This is an interesting question. We have addressed it as such in the discussion:

“While both exploratory behavior and spatial cognition decrease in diabetic rodents, the two do not appear to be tightly correlated, and thus, we do not independently evaluate locomotor activity prior to Y-maze testing.”

What do the authors mean by "The scores for individual animals were of sufficient quality"?

Response: Good question. By “sufficient quality”, we mean that an animal entered at least five arms on Y-maze or that an animal did not have trouble paying attention on OMR, resulting in a falsely low score. We explain this elsewhere in the paper, and worry this wording is confusing here, so we have removed it.

The age-influence (if any) on the performance in the Y-maze test should be discussed.

Response: Thank you. We have added the following to the discussion:

“Age-related decreases in spatial alternation were observed in rats at 9-12 months of age and in exploratory behavior at 12 months of age.”

How might the incidence of diabetic cataract affect the results in the OMR test?

Response: Thank you. We have added the following to the discussion:

“Severe diabetic cataracts can affect OMR. However, diabetic cataracts in rodents appear and/or worsen under anesthesia, and thus, tests like ERG and optical coherence tomography that require anesthesia are affected much more often than OMR, which is performed in awake animals.”

Minor Concerns:

Please, define STZ, OCT, ERG, SF, CS at their first use

Response: Thank you. We have defined these terms at first use.

Instead of: "is used to ablate pancreatic beta cells", it should be: is used to damage pancreatic beta cells

Response: We have made this adjustment.

Which signs should be considered to visualize rodent fatigue?

Response: Thank you. We have added the following to the discussion:

“If a rodent is showing little movement, spending most of its time grooming, or otherwise not looking in the direction of the bars, it may be fatigued. The rodent may be run again on a different day. Additionally, SF and CS testing can be performed on different days, particularly for newer testers who may be slower.”

Data presented here has been modified from data presented in the following two papers:

1. Allen, R. S. *et al.* TrkB signalling pathway mediates the protective effects of exercise in the diabetic rat retina. *Eur J Neurosci.* 47 (10), 1254-1265, doi:10.1111/ejn.13909, (2018).

Thank you for your order!

Dear Rachael Allen,

Thank you for placing your order through Copyright Clearance Center's RightsLink® service.

Order Summary

Licensee:	Rachael Allen
Order Date:	Jun 30, 2020
Order Number:	4858990999016
Publication:	European Journal of Neuroscience
Title:	TrkB signalling pathway mediates the protective effects of exercise in the diabetic rat retina
Type of Use:	Journal/Magazine
Order Total:	0.00 USD

View or print complete [details](#) of your order and the publisher's terms and conditions.

Sincerely,

Copyright Clearance Center

2. Allen, R. S. *et al.* Retinal Deficits Precede Cognitive and Motor Deficits in a Rat Model of Type II Diabetes. *Investigative Ophthalmology & Visual Science.* 60 (1), 123-133, (2019).

This paper is licensed under a [Creative Commons Attribution 4.0 International License](#). Link to license information (information from website has also been pasted below):

<https://creativecommons.org/licenses/by/4.0/>

This is a human-readable summary of (and not a substitute for) the [license](#). [Disclaimer](#).

You are free to:

- **Share** — copy and redistribute the material in any medium or format
- **Adapt** — remix, transform, and build upon the material
- for any purpose, even commercially.
-



- The licensor cannot revoke these freedoms as long as you follow the license terms.

Under the following terms:

- **Attribution** — You must give [appropriate credit](#), provide a link to the license, and [indicate if changes were made](#). You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

- **No additional restrictions** — You may not apply legal terms or [technological measures](#) that legally restrict others from doing anything the license permits.

Notices:

- You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable [exception or limitation](#).
- No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as [publicity, privacy, or moral rights](#) may limit how you use the material.

Data presented here has been modified from data presented in the following two papers:

1. Allen, R. S. *et al.* TrkB signalling pathway mediates the protective effects of exercise in the diabetic rat retina. *Eur J Neurosci.* 47 (10), 1254-1265, doi:10.1111/ejn.13909, (2018).

Thank you for your order!

Dear Rachael Allen,

Thank you for placing your order through Copyright Clearance Center's RightsLink® service.

Order Summary

Licensee:	Rachael Allen
Order Date:	Jun 30, 2020
Order Number:	4858990999016
Publication:	European Journal of Neuroscience
Title:	TrkB signalling pathway mediates the protective effects of exercise in the diabetic rat retina
Type of Use:	Journal/Magazine
Order Total:	0.00 USD

View or print complete [details](#) of your order and the publisher's terms and conditions.

Sincerely,

Copyright Clearance Center

JOHN WILEY AND SONS LICENSE
TERMS AND CONDITIONS
Sep 29, 2020

This Agreement between Rachael Allen ("You") and John Wiley and Sons ("John Wiley and Sons") consists of your license details and the terms and conditions provided by John Wiley and Sons and Copyright Clearance Center.

License Number	4858990999016
License date	Jun 30, 2020
Licensed Content Publisher	John Wiley and Sons
Licensed Content Publication	European Journal of Neuroscience
Licensed Content Title	TrkB signalling pathway mediates the protective effects of exercise in the diabetic rat retina
Licensed Content Author	Rachael S. Allen, Adam M. Hanif, Marissa A. Gogniat, et al
Licensed Content Date	Apr 3, 2018
Licensed Content Volume	47
Licensed Content Issue	10
Licensed Content Pages	12
Type of use	Journal/Magazine
Requestor type	Author of this Wiley article
Is the reuse sponsored by or associated with a pharmaceutical or medical products company?	no
Format	Electronic
Portion	Figure/table
Number of figures/tables	1
Will you be translating?	No
Circulation	10000 - 19999
Title of new article	Behavioral assessment of visual function via optomotor response and cognitive function via Y-maze in diabetic rats
Lead author	Kaavya Gudapati
Title of targeted journal	Journal of Visual Experiments
Publisher	N/A
Expected publication date	Aug 2020

Portions	Figure 2, part A and B. Only a subset of groups. Rachael Allen 844 Alberson Court
Requestor Location	Decatur, GA 30033 United States Attn: Rachael Allen
Publisher Tax ID	EU826007151
Total	0.00 USD
Terms and Conditions	

TERMS AND CONDITIONS

This copyrighted material is owned by or exclusively licensed to John Wiley & Sons, Inc. or one of its group companies (each a "Wiley Company") or handled on behalf of a society with which a Wiley Company has exclusive publishing rights in relation to a particular work (collectively "WILEY"). By clicking "accept" in connection with completing this licensing transaction, you agree that the following terms and conditions apply to this transaction (along with the billing and payment terms and conditions established by the Copyright Clearance Center Inc., ("CCC's Billing and Payment terms and conditions"), at the time that you opened your RightsLink account (these are available at any time at <http://myaccount.copyright.com>).

Terms and Conditions

- The materials you have requested permission to reproduce or reuse (the "Wiley Materials") are protected by copyright.
- You are hereby granted a personal, non-exclusive, non-sub licensable (on a stand-alone basis), non-transferable, worldwide, limited license to reproduce the Wiley Materials for the purpose specified in the licensing process. This license, **and any CONTENT (PDF or image file) purchased as part of your order**, is for a one-time use only and limited to any maximum distribution number specified in the license. The first instance of republication or reuse granted by this license must be completed within two years of the date of the grant of this license (although copies

prepared before the end date may be distributed thereafter). The Wiley Materials shall not be used in any other manner or for any other purpose, beyond what is granted in the license. Permission is granted subject to an appropriate acknowledgement given to the author, title of the material/book/journal and the publisher. You shall also duplicate the copyright notice that appears in the Wiley publication in your use of the Wiley Material. Permission is also granted on the understanding that nowhere in the text is a previously published source acknowledged for all or part of this Wiley Material. Any third party content is expressly excluded from this permission.

- With respect to the Wiley Materials, all rights are reserved. Except as expressly granted by the terms of the license, no part of the Wiley Materials may be copied, modified, adapted (except for minor reformatting required by the new Publication), translated, reproduced, transferred or distributed, in any form or by any means, and no derivative works may be made based on the Wiley Materials without the prior permission of the respective copyright owner. **For STM Signatory Publishers clearing permission under the terms of the [STM Permissions Guidelines](#) only, the terms of the license are extended to include subsequent editions and for editions in other languages, provided such editions are for the work as a whole in situ and does not involve the separate exploitation of the permitted figures or extracts**, You may not alter, remove or suppress in any manner any copyright, trademark or other notices displayed by the Wiley Materials. You may not license, rent, sell, loan, lease, pledge, offer as security, transfer or assign the Wiley Materials on a stand-alone basis, or any of the rights granted to you hereunder to any other person.
- The Wiley Materials and all of the intellectual property rights therein shall at all times remain the exclusive property of John Wiley & Sons Inc, the Wiley Companies, or their respective licensors, and your interest therein is only that of having possession of and the right to reproduce the Wiley Materials pursuant to Section 2 herein during the continuance of this Agreement. You agree that you own no right, title or interest in or to the Wiley Materials or any of the intellectual property rights therein. You shall have no rights hereunder other than the license as provided for above in Section 2. No right, license or interest to any trademark, trade name, service mark or other branding ("Marks") of WILEY or its licensors is

granted hereunder, and you agree that you shall not assert any such right, license or interest with respect thereto

- NEITHER WILEY NOR ITS LICENSORS MAKES ANY WARRANTY OR REPRESENTATION OF ANY KIND TO YOU OR ANY THIRD PARTY, EXPRESS, IMPLIED OR STATUTORY, WITH RESPECT TO THE MATERIALS OR THE ACCURACY OF ANY INFORMATION CONTAINED IN THE MATERIALS, INCLUDING, WITHOUT LIMITATION, ANY IMPLIED WARRANTY OF MERCHANTABILITY, ACCURACY, SATISFACTORY QUALITY, FITNESS FOR A PARTICULAR PURPOSE, USABILITY, INTEGRATION OR NON-INFRINGEMENT AND ALL SUCH WARRANTIES ARE HEREBY EXCLUDED BY WILEY AND ITS LICENSORS AND WAIVED BY YOU.
- WILEY shall have the right to terminate this Agreement immediately upon breach of this Agreement by you.
- You shall indemnify, defend and hold harmless WILEY, its Licensors and their respective directors, officers, agents and employees, from and against any actual or threatened claims, demands, causes of action or proceedings arising from any breach of this Agreement by you.
- IN NO EVENT SHALL WILEY OR ITS LICENSORS BE LIABLE TO YOU OR ANY OTHER PARTY OR ANY OTHER PERSON OR ENTITY FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, INDIRECT, EXEMPLARY OR PUNITIVE DAMAGES, HOWEVER CAUSED, ARISING OUT OF OR IN CONNECTION WITH THE DOWNLOADING, PROVISIONING, VIEWING OR USE OF THE MATERIALS REGARDLESS OF THE FORM OF ACTION, WHETHER FOR BREACH OF CONTRACT, BREACH OF WARRANTY, TORT, NEGLIGENCE, INFRINGEMENT OR OTHERWISE (INCLUDING, WITHOUT LIMITATION, DAMAGES BASED ON LOSS OF PROFITS, DATA, FILES, USE, BUSINESS OPPORTUNITY OR CLAIMS OF THIRD PARTIES), AND WHETHER OR NOT THE PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. THIS LIMITATION SHALL APPLY NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY PROVIDED HEREIN.
- Should any provision of this Agreement be held by a court of competent jurisdiction to be illegal, invalid, or unenforceable, that provision shall be deemed amended to achieve as nearly as possible the same economic effect as the original provision, and the legality, validity and enforceability

of the remaining provisions of this Agreement shall not be affected or impaired thereby.

- The failure of either party to enforce any term or condition of this Agreement shall not constitute a waiver of either party's right to enforce each and every term and condition of this Agreement. No breach under this agreement shall be deemed waived or excused by either party unless such waiver or consent is in writing signed by the party granting such waiver or consent. The waiver by or consent of a party to a breach of any provision of this Agreement shall not operate or be construed as a waiver of or consent to any other or subsequent breach by such other party.
- This Agreement may not be assigned (including by operation of law or otherwise) by you without WILEY's prior written consent.
- Any fee required for this permission shall be non-refundable after thirty (30) days from receipt by the CCC.
- These terms and conditions together with CCC's Billing and Payment terms and conditions (which are incorporated herein) form the entire agreement between you and WILEY concerning this licensing transaction and (in the absence of fraud) supersedes all prior agreements and representations of the parties, oral or written. This Agreement may not be amended except in writing signed by both parties. This Agreement shall be binding upon and inure to the benefit of the parties' successors, legal representatives, and authorized assigns.
- In the event of any conflict between your obligations established by these terms and conditions and those established by CCC's Billing and Payment terms and conditions, these terms and conditions shall prevail.
- WILEY expressly reserves all rights not specifically granted in the combination of (i) the license details provided by you and accepted in the course of this licensing transaction, (ii) these terms and conditions and (iii) CCC's Billing and Payment terms and conditions.
- This Agreement will be void if the Type of Use, Format, Circulation, or Requestor Type was misrepresented during the licensing process.

- This Agreement shall be governed by and construed in accordance with the laws of the State of New York, USA, without regards to such state's conflict of law rules. Any legal action, suit or proceeding arising out of or relating to these Terms and Conditions or the breach thereof shall be instituted in a court of competent jurisdiction in New York County in the State of New York in the United States of America and each party hereby consents and submits to the personal jurisdiction of such court, waives any objection to venue in such court and consents to service of process by registered or certified mail, return receipt requested, at the last known address of such party.

WILEY OPEN ACCESS TERMS AND CONDITIONS

Wiley Publishes Open Access Articles in fully Open Access Journals and in Subscription journals offering Online Open. Although most of the fully Open Access journals publish open access articles under the terms of the Creative Commons Attribution (CC BY) License only, the subscription journals and a few of the Open Access Journals offer a choice of Creative Commons Licenses. The license type is clearly identified on the article.

The Creative Commons Attribution License

The [Creative Commons Attribution License \(CC-BY\)](#) allows users to copy, distribute and transmit an article, adapt the article and make commercial use of the article. The CC-BY license permits commercial and non-

Creative Commons Attribution Non-Commercial License

The [Creative Commons Attribution Non-Commercial \(CC-BY-NC\) License](#) permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.(see below)

Creative Commons Attribution-Non-Commercial-NoDerivs License

The [Creative Commons Attribution Non-Commercial-NoDerivs License](#) (CC-BY-NC-ND) permits use, distribution and reproduction in any medium, provided the original work is properly cited, is not used for commercial purposes and no modifications or adaptations are made. (see below)

Use by commercial "for-profit" organizations

Use of Wiley Open Access articles for commercial, promotional, or marketing purposes requires further explicit permission from Wiley and will be subject to a fee.

Further details can be found on Wiley Online

Library <http://olabout.wiley.com/WileyCDA/Section/id-410895.html>

Other Terms and Conditions:

v1.10 Last updated September 2015

Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or +1-978-646-2777.

2. Allen, R. S. *et al.* Retinal Deficits Precede Cognitive and Motor Deficits in a Rat Model of Type II Diabetes. *Investigative Ophthalmology & Visual Science*. 60 (1), 123-133, (2019).

This paper is licensed under a [Creative Commons Attribution 4.0 International License](https://creativecommons.org/licenses/by/4.0/). Link to license information (information from website has also been pasted below):

<https://creativecommons.org/licenses/by/4.0/>

This is a human-readable summary of (and not a substitute for)
the [license](#). [Disclaimer](#).

You are free to:

- **Share** — copy and redistribute the material in any medium or format
- **Adapt** — remix, transform, and build upon the material
- for any purpose, even commercially.
-



- The licensor cannot revoke these freedoms as long as you follow the license terms.

Under the following terms:

- **Attribution** — You must give [appropriate credit](#), provide a link to the license, and [indicate if changes were made](#). You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
 - **No additional restrictions** — You may not apply legal terms or [technological measures](#) that legally restrict others from doing anything the license permits.
-

Notices:

- You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable [exception or limitation](#).
- No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as [publicity, privacy, or moral rights](#) may limit how you use the material.